47 results
DEFA14A
BLPH
Bellerophon Therapeutics, Inc.
12 Feb 24
Additional proxy soliciting materials
12:39pm
, 2023, the Company was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that, in light
8-K
BLPH
Bellerophon Therapeutics, Inc.
24 Jul 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:10pm
Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that in light of the Company’s previously disclosed workforce reduction plan
8-K
EX-99.1
nwnjfqvg7
26 May 21
Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors
4:05pm
8-K
EX-10.1
dk71atj0rcw8obpasgu
17 Jul 20
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
m3p 003wxu
20 May 20
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
4:04pm
8-K
EX-99.2
hikyc
20 May 20
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
4:04pm
8-K
EX-1.1
rtqcqi nbn0d1z2re1
20 May 20
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
4:04pm
8-K
EX-99.1
vos83kj
20 May 20
Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock
4:04pm